Brief: Nano Dimension Signs Term Sheet With Infinite Epigenetics To Form A Publicly Traded, AI-Powered Preventive Health And Diagnostics Company
15/06/2026 12:39
BRIEF-Nano Dimension Signs Term Sheet With Infinite Epigenetics To Form A Publicly Traded, AI-Powered Preventive Health And Diagnostics Company June 15 (Reuters) - Nano Dimension Ltd 2N5By.F:
NANO DIMENSION SIGNS TERM SHEET WITH INFINITE EPIGENETICS TO FORM A PUBLICLY TRADED, AI-POWERED PREVENTIVE HEALTH AND DIAGNOSTICS COMPANY
NANO DIMENSION - INFINITE EPIGENETICS DEAL VALUED AT $890 MILLION
NANO DIMENSION - SHAREHOLDERS TO RETAIN MINORITY OWNERSHIP AT 20% PREMIUM TO ESTIMATED NET CASH
NANO DIMENSION - MATTHEW DAWSON EXPECTED TO SERVE AS CEO OF COMBINED COMPANY
NANO DIMENSION - PRE-COMBINATION NANO DIMENSION SHAREHOLDERS TO RECEIVE CONTINGENT VALUE RIGHT FOR LEGACY ASSET SALES
Source text: ID:nGNX7jcvw
Further company coverage: [2N5By.F]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nano Dimension
See all newsBrief: Nano Dimension Dismisses KPMG As Independent Registered Public Accounting Firm On Sept 28 - SEC Filing
Brief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Brief: Nano Dimension Q2 Net Income USD -6.804 Million
Brief: Nano Dimension Announces Appointment Of Interim Chief Executive Officer And Chairman Of The Board
Brief: Murchinson-Believes Proposed Nano Dimension Deal Represents Misallocation Of Corporate Resources That Would Significantly Dilute Existing Shareholders